Group consists of nine ventures plus corporate-sponsored innovation projects from Novo Nordisk
News
New PM will ‘inherit an NHS in its most challenging state for decades’
Warning comes from NHS leaders as new Prime Minister prepares to move into Number 10
Sanofi and Regeneron’s Dupixent shows consistent safety profile
Study involving children aged six to 11 years with moderate-to-severe asthma reveals positive data
First patient enrolled in Modus’ sevuparin trial
Research is evaluating the therapy among paediatric patients with severe malaria
Green light for cancer drugs developed by AI specialist Owkin
AI company has its breast cancer and colorectal therapies approved for use in Europe
Avacta announces clinical study of AVA6000
Pro-doxorubicin will advance to the fourth dose following a positive review of safety and tolerability
Manus Bio receives additional funding to combat malaria
Fourth award from the Bill & Melinda Gates Foundation will support artemisinin research
Kaiku Health enters wider partnership with Novartis
Following a successful collaboration, the companies will now partner to focus on precision medicine
Psyomics links up with Hertfordshire Partnership University NHS Foundation Trust
Hertfordshire Trust to invest in mental health care with wide-ranging digital assessment platform
European Commission approves pharma trio’s Ranivisio
Therapy is a biosimilar of Lucentis which treats several serious retinal diseases across the European Union
Novartis’ Scemblix approved by the EC for adults with chronic myeloid leukaemia
It is estimated that every year more than 6,300 people will be diagnosed with CML in Europe
MIT’s AI model can detect Parkinson’s by tracking breathing patterns
The tool uses a series of connected algorithms that can assess if someone has PD from their nocturnal breathing
Pfizer’s RSV vaccine candidate shows promise in older adults study
It is estimated that RSV infections in older adults account for 177,000 hospitalisations and 14,000 deaths each year in the US alone
Janssen’s teclistamab gets CMA from European Commission
Teclistamab is the first bispecific antibody worldwide to be approved for patients with relapsed and refractory multiple myeloma
Alpha Cognition announces bioequivalence study results for Alzheimer’s
In 2019, there were over 850,000 people with dementia in the UK, representing one in every 14 people aged 65 and over
